Frequently Asked Questions

The earliest signs are often subtle and easy to dismiss — unexplained fatigue, shortness of breath on mild exertion, swollen ankles, or foamy urine. Carpal tunnel syndrome in both hands without an obvious cause is also a recognised early sign. The challenge is that none of these symptoms are specific to AL amyloidosis, which is why awareness matters so much.

The serum free light chain (FLC) assay is the most sensitive first-line blood test for AL amyloidosis. It measures the levels of kappa and lambda light chains in your blood and the ratio between them. An abnormal ratio is often the first clue that something is wrong. SPEP and UPEP (protein electrophoresis from blood and urine) are also part of the standard workup.

On average, 2 to 3 years from first symptoms — and many patients see five or more doctors before getting the correct answer. This is not because doctors are not thorough. It is because AL amyloidosis mimics so many other conditions. If you have been chasing unexplained symptoms across multiple organs without a clear answer, ask specifically about an amyloidosis screen.

Constantly. Cardiac AL is frequently mistaken for hypertensive heart disease or hypertrophic cardiomyopathy. Renal AL is often attributed to diabetic nephropathy. Peripheral neuropathy is mistaken for diabetes or idiopathic causes. GI involvement is frequently diagnosed as IBS. This is why it earned the name The Chameleon Disease.

Yes. A tissue biopsy stained with Congo red dye is required to confirm amyloid deposits. The most common first biopsy is an abdominal fat pad biopsy, which is minimally invasive. If this is negative but suspicion remains high, a biopsy of the affected organ may be needed. A bone marrow biopsy is also usually performed to identify and quantify the plasma cell clone.

Usually as soon as possible, particularly if the heart or kidneys are involved. Organ damage can progress quickly in AL amyloidosis, and delaying treatment gives amyloid more time to accumulate. Your hematologist will typically want to begin treatment within weeks of a confirmed diagnosis, not months.

Hair loss depends on the specific drugs used. The most commonly used regimens for AL amyloidosis today, including daratumumab-based combinations, do not typically cause significant hair loss. Older regimens involving melphalan may cause some thinning. Ask your hematologist specifically about the side effect profile of your planned treatment.

Yes, relapse is possible, particularly if the plasma cell clone is not fully eliminated. This is why your care team monitors your free light chain levels and other markers closely during and after treatment. If your disease does relapse, there are further treatment options available, including newer targeted therapies and clinical trials such as NXC-201 CAR-T therapy.

Remission means the disease is no longer detectable or is no longer progressing. A complete hematologic response means the abnormal light chains are undetectable in your blood and urine. This can last for many years. Cure is a stronger word and is used more cautiously — some patients with prolonged complete responses may effectively be cured, but ongoing monitoring is still recommended.

Many people do, depending on the treatment type, how well they tolerate it, and which organs are affected. Daratumumab-based chemotherapy is often given in outpatient settings, which makes it more compatible with daily life than inpatient regimens. Fatigue is the most common limiting factor. Talk to your care team about what is realistic for your specific situation.

Be present without trying to fix everything. The most powerful thing you can do in the early days is listen, help with practical tasks, and go to appointments together. Take notes. Ask questions the patient forgets to ask. Let them set the pace for how much information they want to take in at once. And ask them directly what kind of support feels most helpful — everyone is different.

No. AL amyloidosis is not contagious in any way. It develops from an abnormal change in a person's own plasma cells and cannot be passed from one person to another through contact, shared items, or any other means.

A written list of questions prepared before the appointment. A notepad or phone to take notes during it. A list of all current medications and doses. Any recent test results or letters from other specialists. And ideally, the name and contact details of the GP, so the specialist team can communicate directly. Do not be afraid to ask the team to repeat or explain anything that is unclear.

It starts with that your wellbeing matters — not just for your sake but because sustained caregiving requires you to be well. Connect with other caregivers through support groups. Be honest with your own GP about the stress you are carrying. Accept help when it is offered. And give yourself permission to have feelings about what is happening — grief, fear, and exhaustion are all valid responses to a very difficult situation.

Yes. Several organisations offer grants and assistance for patients and families managing serious illness, including the Patient Advocate Foundation, Chive Charities, and the Patient Access Network (PAN) Foundation, which has a specific fund for amyloidosis. The Amyloidosis Foundation also provides guidance on financial resources. Ask your care team about a social worker referral — they are often the best first step in navigating financial support.

The serum free light chain (FLC) assay combined with serum and urine protein electrophoresis (SPEP/UPEP) provides the highest sensitivity for detecting the underlying plasma cell dyscrasia. FLC alone has greater than 97% sensitivity for AL amyloidosis when combined with SPEP. Neither test alone is sufficient — both should be ordered together when AL amyloidosis is suspected.

Both show increased LV wall thickness, but several features help distinguish them. Cardiac AL more commonly shows low-voltage ECG despite increased wall thickness (voltage-to-mass dissociation). Apical-sparing on global longitudinal strain (GLS) imaging is a highly specific sign for cardiac amyloidosis generally. Tc-99m PYP scintigraphy (bone scan) strongly favours ATTR when positive. FLC assay and tissue biopsy are required to confirm AL.

As soon as AL amyloidosis is confirmed, or strongly suspected based on clinical and laboratory findings. Do not wait for organ function to deteriorate before referring. Specialist centres offer multidisciplinary assessment, access to clinical trials including CAR-T therapy, and the cumulative experience of managing complex presentations that most generalist settings will not encounter frequently. Earlier referral consistently improves outcomes.